{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003230","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.739679+00:00","generated_at":"2026-06-19T07:45:47.765618+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Cytokinetics amends bylaws to add forum selection provisions for derivative and Securities Act claims","bullets":["New Article X designates Delaware courts as exclusive forum for derivative suits, fiduciary duty, and corporate governance claims.","Federal district courts set as exclusive forum for claims under the Securities Act of 1933.","Board reserved the right to consent to an alternative forum in writing when deemed appropriate.","Amendment effective February 14, 2023; prior Article X renumbered to Article XI.","Purpose is to reduce risk of duplicative litigation and inconsistent outcomes across multiple forums."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003230","json":"https://secwatch.observer/filing/0000950170-23-003230.json","markdown":"https://secwatch.observer/filing/0000950170-23-003230.md","text":"https://secwatch.observer/filing/0000950170-23-003230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023003230/0000950170-23-003230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023003230/cytk-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:45:47.765618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a827a21a5644f7d8c42da5839b3eb557343c8bb","claim":"CYTOKINETICS INC: Added Article X providing exclusive forum selection provisions and renumbered existing Article X to Article XI (effective 2023-02-14).","evidence_excerpt":"On and effective as of February 14, 2023, the Board of Directors (the “Board”) of Cytokinetics, Incorporated approved and adopted Amended and Restated Bylaws of Cytokinetics (the “Revised Bylaws”) for the purposes of: (a) renumbering Article X thereof to be Article XI, and (b) adding a new Article X thereof (i) to provide that, unless Cytokinetics consents in writing to the selection of an alternative forum, specified courts in Delaware shall be the exclusive forum for resolving certain disputes under corporate law, and the federal district courts of the United States shall be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, to the fullest extent permitted by law, and (c) to make certain technical revisions as set forth therein.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023003230/0000950170-23-003230-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}